Uncertainties Remain as SDI Scheme Meeting Set Amid Regulatory and Approval Conditions

Court Greenlights SDI Scheme Meeting Amid Acquisition by Beijing Guoci Subsidiary

SDI Limited (ASX:SDI) has cleared a key regulatory hurdle as the Supreme Court of New South Wales ordered the company to convene a shareholder meeting to vote on the proposed acquisition by InnoXvest Dental Pty Ltd, a wholly owned subsidiary of Beijing Guoci Kebo Technology Co., Ltd. The court’s approval follows the Australian Securities and Investments Commission’s registration of the scheme booklet, which lays out the terms of the $1.40 per share all-cash offer, representing a substantial premium over recent trading prices.

The scheme booklet, now formally registered by ASIC, includes an independent expert report from RSM Corporate Australia Pty Ltd, which concludes that the scheme is fair and reasonable and in the best interests of SDI shareholders, assuming no superior proposal emerges. The offer price reflects a 58% premium to SDI’s last closing price before the scheme announcement and a 53–56% premium to various volume weighted average prices over the preceding 30, 90, and 180 days.

SDI’s board has thrown its full weight behind the scheme, unanimously recommending that shareholders vote in favour of the transaction, subject to the independent expert’s ongoing support and the absence of a superior proposal. Notably, the board members, who collectively control approximately 47.29% of SDI shares, have committed to voting their holdings in favour of the scheme. Jeffery Cheetham, SDI’s founder and largest shareholder with a 45.3% stake, alongside his controlled entities, have also pledged support, underscoring the transaction’s strong internal backing.

The shareholder meeting is scheduled as a virtual event on 22 June 2026, with voting eligibility set as of 7:00pm on 20 June 2026. Proxy voting instructions have been provided, and shareholders are encouraged to participate online or by proxy. The scheme booklet provides comprehensive guidance on voting procedures and the implications of the scheme.

Strategic Rationale and Transaction Details

Founded in 1972 and listed since 1985, SDI is a leading Australian manufacturer and global distributor of specialist dental materials, including amalgams, composites, adhesives, and tooth whitening systems. The acquisition by Beijing Guoci, controlled by Shenzhen Stock Exchange-listed Shandong Sinocera Functional Material Co. Ltd, aligns with Sinocera’s strategic expansion into the Australian manufacturing market and the dental materials sector.

Sinocera intends to maintain SDI’s operations substantially as they are, including the Bayswater head office and manufacturing facility, while leveraging potential synergies in product development and global market channels. Post-transaction, SDI will be delisted from the ASX and become a wholly owned subsidiary of InnoXvest Dental.

The scheme is subject to several conditions precedent, including Foreign Investment Review Board (FIRB) approval, Chinese regulatory approvals from the National Development and Reform Commission, Ministry of Commerce, and State Administration of Foreign Exchange, as well as final court approval and shareholder approval by the requisite majorities. As of the date of the scheme booklet, approvals from NDRC and MOFCOM have been obtained, with FIRB approval pending.

Funding for the transaction is secured through a combination of Sinocera equity commitment (40%) and a debt facility arranged by Midco, an indirect wholly owned subsidiary of Sinocera, covering 60% of the scheme consideration. The total maximum consideration payable is approximately A$166.4 million based on the current fully diluted share capital.

Key Risks and Considerations for Shareholders

While the scheme offers SDI shareholders certainty of value with a significant premium, it also entails foregoing any future upside from continued ownership and exposes shareholders to tax consequences, including potential capital gains tax events. The scheme booklet advises shareholders to seek independent financial, legal, and tax advice tailored to their circumstances.

Risks remain around the timing and satisfaction of regulatory approvals, the possibility of a superior proposal emerging before the scheme meeting, and the execution risks associated with integrating SDI into Sinocera’s operations. The scheme implementation will incur transaction costs estimated at approximately A$10.2 million, with an additional reimbursement fee payable by SDI to Bidder in certain termination scenarios.

Should the scheme not proceed, SDI will remain listed and subject shareholders to ongoing business risks, including regulatory changes, market competition, and operational execution challenges. The board cautions that SDI’s share price may decline below the scheme consideration in the absence of a competing proposal.

Independent Expert Confirms Scheme Fairness and Reasonableness

RSM Corporate Australia’s independent expert report, included in the scheme booklet, values SDI shares on a controlling basis between A$1.21 and A$1.38, with a preferred valuation of A$1.29 per share. The scheme consideration of A$1.40 per share exceeds this range, supporting the conclusion that the offer is fair.

RSM also considers the scheme reasonable, highlighting the premium to recent share prices, the risk of share price decline if the scheme fails, and the opportunity for shareholders to realise their investment in cash without brokerage fees. The report notes that no superior proposals have been received, and the market has reacted positively to the scheme announcement, with share prices trading above pre-announcement levels.

What to Watch Next

Investors will be closely monitoring the shareholder vote on 22 June 2026 and the receipt of remaining regulatory approvals, particularly FIRB consent. The timing of court approval and scheme implementation remains subject to these conditions and potential unforeseen delays.

With the SDI board and major shareholders aligned in support, the scheme appears poised for approval barring any last-minute developments. However, questions linger about the strategic integration under Sinocera’s ownership and the impact on SDI’s operations and workforce. The transaction bonuses awarded to certain directors may also attract scrutiny from some shareholders wary of conflicts of interest.

Meanwhile, the broader dental materials sector continues to face regulatory pressures, notably the phase-out of amalgam products, which SDI is addressing through new product launches and manufacturing investments, as detailed in prior company updates. The acquisition by a major Chinese materials player underscores the increasing globalization and consolidation in this niche manufacturing space.

For shareholders weighing their options, the scheme booklet and expert report provide essential context, but the ultimate decision will hinge on individual risk tolerance, tax considerations, and views on SDI’s standalone prospects versus the certainty of the cash offer.

SDI acquisition and Montrose project progress have been critical recent developments shaping shareholder sentiment and valuation.